FDA warning letter · Biologics

BioStem Life Sciences

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)].** For example,

Citations in the original letter

As cited in this historical letter, not a statement of current regulatory requirements.

  • 21 CFR 1271.10(a)
  • 21 CFR 1271
  • 21 CFR 1271.15
  • 21 CFR 1271.3(d)
  • 21 CFR 1271.10(a)(1)
  • 21 CFR 1271.3(f)(1)
  • 21 CFR 1271.3(c)
  • 21 CFR 1271.1
  • 21 CFR 1271.20
  • 21 CFR 210
  • 21 CFR 211.42(c)(10)(iv)
  • 21 CFR 211.42(c)(10)(v)
  • 21 CFR 211.100(a)
  • 21 CFR 211.160(b)
  • 21 CFR 211.166(a)
  • 21 CFR 211.113(b)